Reading INCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INCY free→Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Intact
$99.75-2.19%
Close 2026-06-16 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, while earnings quality and management's track record are neutral. Risk is moderate, and the sector backdrop presents a headwind. Peer multiples imply a price about 19% above where it trades (it looks cheap on this basis); the read is fair. The outlook hinges on guidance changes and sector trends, particularly the performance of key Healthcare bellwethers. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $21.68B
- Employees
- —
- IPO date
- 1996-05-15
- Next earnings
- 2026-08-04
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 7 valuation methods, at three horizons. Current price $99.75. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfair
$122.88consensus
Range $111.92 – $147.74
vs price: -19% below
Method agreement — · 7 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$228.14consensus
Range $183.22 – $369.64
vs price: -56% below
Method agreement — · 5 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peershigh confidence
At $102 INCY trades at 14× p/e, below its 17× p/e peer median. Our $126 fair value sits above the price; high confidence. Analysts: $90–$140. Not investment advice.
Multiple (P/E)
13.7x
peer 16.8x · own history 20.5x
Premium
0.8x peer
0.7x its own history
Growth the price needs
-19%
our forecast 19%
Our fair value
$126.13
range $110.04 – $148.65
Analyst range(a guide on our number, not a target)Our number is in the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fairfair12-month view
What's priced inJustified
The price implies about 19% below a flat-multiple fair value, below our forecast of about 19%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
84th pctl · Health Care
Earnings quality
neutralOver the trailing year it converted 1.06x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
31st pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity.
Management & capital allocation
neutralEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Bullish19 analysts, 38% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $1.83 → $1.82 (-0.5% / 30d). 10 raised, 5 cut, 19 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 2 maintained. 38% of analysts rate Buy.
Price target activity
4 PT revisions / 30d. Avg target 15.7% above current price.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- strong
- Post-call reaction
- strong
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$120.
How much price usually moves either way.
On a bad day, this stock has moved -$289.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,833.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceQuartersactive 4d
Watch for the Vega Therapeutics deal to finish.
Why it matters: Finishing this deal would grow Incyte's hematology portfolio. It would add a new therapy for bleeding disorders.
What confirms / what disproves
Confirms:The acquisition will close in Q3 2026 if there are no regulatory delays.
Disproves:The deal is delayed or blocked by rules.
Material event
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-06-134d agoInvesting.com
Advances: Increase Hematology and Oncology sales
Positive trial results support growth in oncology sales.
Strongly reinforcesUnconfirmed report
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting INCY and other Healthcare names. Worth watching these names for early signals.
- If INCY raises forward guidance on the next earnings call (currently NEW as of 2026-04-28), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If INCY beats again next quarter like it did this past one (a big beat of +35% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
Downside triggers
- If INCY cuts guidance on the next call (currently NEW as of 2026-04-28), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping INCY and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-281mo agoItem 2.02
Results of Operations and Financial Condition. On April 28, 2026 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1.
Earnings preannouncementpositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+1.0 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.